Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Overview

USA - NASDAQ:TXG - US88025U1097 - Common Stock

11.72 USD
-0.23 (-1.92%)
Last: 9/26/2025, 7:10:07 PM
11.72 USD
0 (0%)
After Hours: 9/26/2025, 7:10:07 PM

TXG Key Statistics, Chart & Performance

Key Statistics
52 Week High22.89
52 Week Low6.78
Market Cap1.46B
Shares124.49M
Float112.27M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.78
PEN/A
Fwd PEN/A
Earnings (Next)10-27 2025-10-27/amc
IPO09-12 2019-09-12
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


TXG short term performance overview.The bars show the price performance of TXG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

TXG long term performance overview.The bars show the price performance of TXG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of TXG is 11.72 USD. In the past month the price decreased by -17.93%. In the past year, price decreased by -48.3%.

10X GENOMICS INC-CLASS A / TXG Daily stock chart

TXG Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 21.21 175.30B
DHR DANAHER CORP 24.55 132.35B
A AGILENT TECHNOLOGIES INC 22.64 34.98B
IQV IQVIA HOLDINGS INC 15.65 30.53B
MTD METTLER-TOLEDO INTERNATIONAL 29.45 24.81B
WST WEST PHARMACEUTICAL SERVICES 37.57 18.81B
WAT WATERS CORP 23.85 17.36B
ILMN ILLUMINA INC 22.04 14.09B
MEDP MEDPACE HOLDINGS INC 36.94 13.95B
TEM TEMPUS AI INC N/A 13.63B
ICLR ICON PLC 12.38 12.74B
RVTY REVVITY INC 17.19 9.76B

About TXG

Company Profile

TXG logo image 10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. The company is headquartered in Pleasanton, California and currently employs 1,306 full-time employees. The company went IPO on 2019-09-12. The firm's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

Company Info

10X GENOMICS INC-CLASS A

6230 Stoneridge Mall Road

Pleasanton CALIFORNIA 94588 US

CEO: Serge Saxonov

Employees: 1306

TXG Company Website

TXG Investor Relations

Phone: 19254017300

10X GENOMICS INC-CLASS A / TXG FAQ

What is the stock price of 10X GENOMICS INC-CLASS A today?

The current stock price of TXG is 11.72 USD. The price decreased by -1.92% in the last trading session.


What is the ticker symbol for 10X GENOMICS INC-CLASS A stock?

The exchange symbol of 10X GENOMICS INC-CLASS A is TXG and it is listed on the Nasdaq exchange.


On which exchange is TXG stock listed?

TXG stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for 10X GENOMICS INC-CLASS A stock?

22 analysts have analysed TXG and the average price target is 15.3 USD. This implies a price increase of 30.55% is expected in the next year compared to the current price of 11.72. Check the 10X GENOMICS INC-CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is 10X GENOMICS INC-CLASS A worth?

10X GENOMICS INC-CLASS A (TXG) has a market capitalization of 1.46B USD. This makes TXG a Small Cap stock.


How many employees does 10X GENOMICS INC-CLASS A have?

10X GENOMICS INC-CLASS A (TXG) currently has 1306 employees.


What are the support and resistance levels for 10X GENOMICS INC-CLASS A (TXG) stock?

10X GENOMICS INC-CLASS A (TXG) has a support level at 11.71 and a resistance level at 13.03. Check the full technical report for a detailed analysis of TXG support and resistance levels.


Is 10X GENOMICS INC-CLASS A (TXG) expected to grow?

The Revenue of 10X GENOMICS INC-CLASS A (TXG) is expected to grow by 2.07% in the next year. Check the estimates tab for more information on the TXG EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy 10X GENOMICS INC-CLASS A (TXG) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does 10X GENOMICS INC-CLASS A (TXG) stock pay dividends?

TXG does not pay a dividend.


When does 10X GENOMICS INC-CLASS A (TXG) report earnings?

10X GENOMICS INC-CLASS A (TXG) will report earnings on 2025-10-27, after the market close.


What is the Price/Earnings (PE) ratio of 10X GENOMICS INC-CLASS A (TXG)?

10X GENOMICS INC-CLASS A (TXG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).


What is the Short Interest ratio of 10X GENOMICS INC-CLASS A (TXG) stock?

The outstanding short interest for 10X GENOMICS INC-CLASS A (TXG) is 12.24% of its float. Check the ownership tab for more information on the TXG short interest.


TXG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TXG Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TXG. TXG has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TXG Financial Highlights

Over the last trailing twelve months TXG reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 61.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -8.63%
ROE -10.94%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%187.5%
Sales Q2Q%12.93%
EPS 1Y (TTM)61.39%
Revenue 1Y (TTM)2.02%

TXG Forecast & Estimates

22 analysts have analysed TXG and the average price target is 15.3 USD. This implies a price increase of 30.55% is expected in the next year compared to the current price of 11.72.

For the next year, analysts expect an EPS growth of 55.3% and a revenue growth 2.07% for TXG


Analysts
Analysts73.64
Price Target15.3 (30.55%)
EPS Next Y55.3%
Revenue Next Year2.07%

TXG Ownership

Ownership
Inst Owners103.23%
Ins Owners1.72%
Short Float %12.24%
Short Ratio4.73